Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the sacroiliac joints and spine. It leads to inflammation and new bone growth in the joints of the spine and sacrum. Some common symptoms of axSpA include lower back pain, morning stiffness, fatigue, and restricted spinal movement. Currently, biological disease-modifying anti-rheumatic drugs (bDMARDs) such as tumor necrosis factor inhibitors (TNFi) are the mainstay of treatment for axSpA.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the Axial Spondyloarthritis (axSpA) Treatment market are Pfizer, AbbVie, Janssen, UCB, Novartis, Celgene, Eli Lilly and Company and Amgen.
The high prevalence of Axial Spondyloarthritis (AXSPA) Treatment Market around the world presents lucrative growth opportunities for players in this market. Moreover, increasing awareness about early diagnosis and treatment is further expected to boost demand.
Technological advancements include the development of new biologic therapies such as pipeline drugs targeting interleukin-17, interleukin-23, small molecules, biosimilars and Janus kinase inhibitors which can improve treatment outcomes and quality of life for patients.
Market Drivers
Increasing research into the pathogenesis of axSpA has helped identify new treatment targets, driving the development of novel therapies. Biologics such as TNF inhibitors have demonstrated high efficacy in relieving symptoms and are gradually becoming the standard of care for patients with active axSpA. However, their high cost remains a major challenge, indicating significant opportunities for cheaper biosimilars or targeted small molecule alternatives.
Current challenges in Axial Spondyloarthritis (axSpA) Treatment Market
Axial spondyloarthritis has a delayed diagnosis rate. The average delay between symptom onset and diagnosis is 8-10 years. Symptoms of axSpA are similar to other musculoskeletal conditions, making it difficult to correctly diagnose in the early stages. Rheumatologists and other healthcare providers lack knowledge about the condition. Many primary care physicians and rheumatologists are still not adequately educated about axSpA and its diagnosis criteria. Early axSpA may initially present with back pain alone, without obvious signs of inflammation. This back pain is often attributed to other causes like muscle strain or minor injuries.
SWOT Analysis
Strength: Drugs like biosimilars and JAK inhibitors with novel mechanisms of action provide improved treatment options. They have high efficacy in relieving signs and symptoms of axSpA.
Weakness: High drug development costs and price pressures limit investments in this segment. Biologic drugs require injections or infusions that deter patient compliance.
Opportunity: Increasing awareness campaigns help improve early diagnosis rate and treatment seeking behavior. Expanding role of rheumatologists and formation of collaborative care networks.
Threats: Safety risks and side effects of long-term immunosuppressant use. Rising healthcare costs and budget constraints of governments and insurers.
Major geographical regions in terms of axSpA treatment market value are North America and Europe. North America accounts for the largest share globally due to high healthcare expenditure and relatively easier access to novel therapies. Europe is the second largest regional market supported by rising disease prevalence and government reimbursement.
The Asia Pacific region is expected to be the fastest growing market for axSpA treatment during the forecast period. This is attributed to improving access to healthcare facilities, increasing disposable incomes, and growing prevalence of axial spondyloarthritis in developing countries.
Get This Report in Japanese Language: 軸性脊椎関節炎治療市場
Get This Report in Korean Language: 축성 척추관절염치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
